Symbion Announces Program to Provide Process Control Solutions
News Apr 11, 2006
Symbion™ Systems has announced the launching of a major program to provide process control solutions to reduce the total cost of ownership of analytical process analyzers for industries such as hydrocarbon processing, chemical manufacturing, paper and semiconductors.
This program results in part from a recent agreement with GE to supply process control software based on architecture developed by Symbion.
"Recently, Symbion Systems signed an agreement with GE Fanuc Automation to develop and market process analytical technology software to diverse industries, with particular emphasis on on-line process analysis," said W. Michael Doyle, Symbion Systems’ president.
"Under the new agreement, GE Fanuc will have exclusive rights to market the PAT software for use in life sciences process analysis while Symbion will take the lead in providing analytical software to industries other than the life sciences."
"While the details of the agreement remain confidential, the deal means our company’s capabilities will benefit substantially from the increased financial resources, ongoing revenue stream, and multiyear shared product development resulting from the GE alliance. We expect the impact to be far reaching and sustained."
In the traditional world of distributed control systems (DCS), relatively simple sensors are used to provide one dimensional (scalar) information which can be processed directly by the DCS.
With the advent of process analytical technology, the situation has drastically changed. An analytical instrument, such as a near–infrared spectrometer, may provide as many as 2,000 independent spectral data points in less than a second.
This large amount of data must be collected, stored, displayed, transmitted, and processed in such a way as to provide timely and manageable information about the process variables of interest.
Symbion fills this role by bridging the gap between the instrumentation at the manufacturing process and the data historian, SCADA, or other enterprise–level data system.
Symbion claims that, for senior managers charged with streamlining their manufacturing processes and who experience difficulty with implementing or maintaining traditional analytical process control solutions that are simply modified laboratory control software, Symbion’s software provides a seamless alternative by taking the difficulty out of implementation and greatly reducing the cost of deploying analytical process analyzers.
Applications addressed by Symbion Systems process analytical software suites include hydrocarbon processing, specialty chemicals, polymer streams, paper viscosity control, waste water analysis and the profiling of optical coatings on silicon wafers during semiconductor manufacturing processes.
At the heart of Symbion’s solutions are three analytical software suites. Symbion-DX™ and Symbion-RX™ provide a standard process analytical software environment for controlling, sequencing and networking analytical instruments, sampling systems and data analysis routines.
Symbion – LX™ is an analytical laboratory software suite for spectroscopic analysis, connectivity, compliance and control.
Modified Form of Botox Could Replace Opioids as Treatment for Chronic PainNews
A modified form of botulinum toxin gives long-lasting pain relief in mice without adverse effects and, in time, could replace opioid drugs as a safe and effective way of treating chronic pain, according to new research.READ MORE
Key Ingredient in Diabetes Drug Modified to Improve Side EffectsNews
Improved medications for Type 2 diabetes are one step closer thanks to a new discovery reported this week. By modifying the key ingredient in current diabetes drugs, the researchers produced a compound that was effective for hyperglycemia in animal trials, yet without the most problematic side effects of current drugs.READ MORE
Tackling Cancer at Ground Zero: Designer Molecule Inhibits Protein TargetNews
A new molecule designed by University of Adelaide researchers shows great promise for future treatment of many cancers. The new molecule successfully targets a protein that plays a major role in the growth of most cancers.READ MORE